Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.60 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.60 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31072982 | 1.00 | MAPT (0.64) | MAPTRAB9ACHRNB2CHRNA4CHRNB4 | |
| Hydrochloric Acid SCHEMBL5036857 | 0.99 | MAPT (0.63) | MAPTRAB9ACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL29437403 | 0.83 | MAPT (0.72) | MAPTRAB9ACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL21541940 | 0.83 | MAPT (0.72) | MAPTRAB9ACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL2725735 | 0.83 | MAPT (0.72) | MAPTRAB9ACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL29742107 | 0.81 | MAPT (0.69) | MAPTRAB9ACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL1392965 | 0.81 | MAPT (0.89) | MAPTRAB9ACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL161270 | 0.81 | MAPT (0.69) | MAPTRAB9ACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL18053605 | 0.80 | MAPT (0.71) | MAPTRAB9ACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL23104683 | 0.79 | MAPT (0.63) | MAPTRAB9ACHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225268-A1 | Diazabicyclic CNS active agents | ABBVIE INC. | 2003-12-04 | — | — | US | claimed |
| US-7265115-B2 | Diazabicyclic CNS active agents | ABBOTT LABORATORIES (US) | 2007-09-04 | — | — | US | disclosed |
| US-20030225268-A1 | Diazabicyclic CNS active agents | ABBVIE INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1359152-A2 | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | ABBOTT LABORATORIES (US) | 2003-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225268-A1 | Diazabicyclic CNS active agents | GABRE, GRIN1, CNTN1 | MAPT 2125/4885RAB9A 579/4885CHRNB2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.